

eXegenics Inc
 Form 3
 March 29, 2007

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Eichler David A		(Month/Day/Year)	eXegenics Inc [EXEG]	
(Last)	(First)	(Middle)	03/27/2007	
625 AVENUE OF THE AMERICAS, 4TH FLOOR			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
NEW YORK,Â NYÂ 10011			<input checked="" type="checkbox"/> Director	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input type="checkbox"/> 10% Owner	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			<input type="checkbox"/> Officer	<input type="checkbox"/> Form filed by More than One Reporting Person
			(give title below)	(specify below)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

(Instr. 5)

Series C Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	9,081,500	\$ 0	I	See Footnote (2)
Warrant (Right to Buy)	Â (3)	03/27/2017	Common Stock	1,135,188	\$ 0.002	I	See Footnote (2)
Warrant (Right to Buy)	Â (3)	03/27/2017	Common Stock	309,737	\$ 0.6728	I	See Footnote (2)
Warrant (Right to Buy)	Â (3)	03/27/2017	Common Stock	309,737	\$ 0.8473	I	See Footnote (2)
Warrant (Right to Buy)	Â (3)	03/27/2017	Common Stock	309,737	\$ 1.0466	I	See Footnote (2)
Stock Option (Right to Buy)	Â (4)	11/08/2014	Common Stock	25,947	\$ 0.04	I	See Footnote (2)
Stock Option (Right to Buy)	Â (4)	02/15/2015	Common Stock	103,788	\$ 0.04	I	See Footnote (2)
Stock Option (Right to Buy)	Â (5)	02/28/2016	Common Stock	155,682	\$ 0.05	I	See Footnote (2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Eichler David A 625 AVENUE OF THE AMERICAS, 4TH FLOOR NEW YORK, NY 10011	Â X	Â	Â	Â

Signatures

/s/ David A.
Eichler

03/29/2007

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares are currently exercisable and do not expire.
- (2) As Managing Director of Psilos Group Investors II-S, LLC, the General Partner of Psilos Group Partners II SBIC, L.P.
- (3) These warrants are currently exercisable.
- (4) These options are fully vested.
- (5) 56,218.83 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.

Â

Remarks:

All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. Â

Edgar Filing: eXegenics Inc - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.